Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
72,000
Merck & Co Inc News & Analysis
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
stocks
What did Morningstar subscribers buy and sell during earnings season?
And what do our analysts think of the stocks and ETF?
personal-finance
5 investing rules I break in my portfolio
Don’t let perfect investing be the enemy of good
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,550.30 | 36.60 | -0.43% |
| CAC 40 | 7,409.57 | 11.37 | -0.15% |
| DAX 40 | 20,405.92 | 20.35 | -0.10% |
| Dow JONES (US) | 43,828.06 | 86.06 | -0.20% |
| FTSE 100 | 8,300.33 | 11.43 | -0.14% |
| HKSE | 19,971.24 | 425.81 | -2.09% |
| NASDAQ | 19,926.72 | 23.88 | 0.12% |
| Nikkei 225 | 39,470.44 | 378.70 | -0.95% |
| NZX 50 Index | 12,754.26 | 61.54 | 0.48% |
| S&P 500 | 6,051.09 | 0.16 | -0.00% |
| S&P/ASX 200 | 8,296.00 | 34.30 | -0.41% |
| SSE Composite Index | 3,391.88 | 69.62 | -2.01% |